1-(3-溴丙基)-2,4-二氯苯 | 93962-66-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(3-溴丙基)-2,4-二氯苯
• 英文名称: 1-(3-Bromopropyl)-2,4-dichlorobenzene
• CAS: 93962-66-4
• 化学式: C₉H₉BrCl₂
• 分子量: 267.98
• InChiKey: CSYYXSGFVDABMR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

安全信息

• 海关编码：
  2903999090

反应信息

• 作为反应物：
  描述：

  1-(3-溴丙基)-2,4-二氯苯 在 sodium methylate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 20.17h， 生成 Methyl 4-[3-(2,4-dichlorophenyl)propylsulfanyl]-3-oxobutanoate
  参考文献：
  名称：

  ATP-Citrate Lyase as a Target for Hypolipidemic Intervention. Design and Synthesis of 2-Substituted Butanedioic Acids as Novel, Potent Inhibitors of the Enzyme

  摘要：

  ATP-citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Inhibitors of the enzyme represent a potentially novel class of hypolipidemic agent, which are anticipated to have combined hypocholesterolemic and hypotriglyceridemic properties. A series of a-substituted butanedioic acids have been designed and synthesized as inhibitors of the enzyme, The best compounds, 58, 68, 71, 74 have reversible K-i's in the 1-3 mu M range against the isolated rat enzyme, As representative of this compound class, 58, has been shown to exert its inhibitory action through a mainly competitive mechanism with respect to citrate and a noncompetitive one with respect to CoA. None of the inhibitors were able to inhibit cholesterol and/or fatty acid synthesis in HepG2 cells. This has been attributed to the adverse physicochemical properties of the molecules leading to a lack of cell penetration. Despite this, a lead structural class of compound has been identified with the potential for modification into potent, cell-penetrant, and efficacious inhibitors of ATP-citrate lyase.

  DOI：

  10.1021/jm960167w
• 作为产物：
  描述：

  3-(2,4-二氯苯基)-2-丙烯-1-醇 在 platinum(IV) oxide N-溴代丁二酰亚胺(NBS) 、 氢气 、 三苯基膦 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 20.0 ℃ 、344.73 kPa 条件下， 反应 0.42h， 生成 1-(3-溴丙基)-2,4-二氯苯
  参考文献：
  名称：

  ATP-Citrate Lyase as a Target for Hypolipidemic Intervention. Design and Synthesis of 2-Substituted Butanedioic Acids as Novel, Potent Inhibitors of the Enzyme

  摘要：

  ATP-citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Inhibitors of the enzyme represent a potentially novel class of hypolipidemic agent, which are anticipated to have combined hypocholesterolemic and hypotriglyceridemic properties. A series of a-substituted butanedioic acids have been designed and synthesized as inhibitors of the enzyme, The best compounds, 58, 68, 71, 74 have reversible K-i's in the 1-3 mu M range against the isolated rat enzyme, As representative of this compound class, 58, has been shown to exert its inhibitory action through a mainly competitive mechanism with respect to citrate and a noncompetitive one with respect to CoA. None of the inhibitors were able to inhibit cholesterol and/or fatty acid synthesis in HepG2 cells. This has been attributed to the adverse physicochemical properties of the molecules leading to a lack of cell penetration. Despite this, a lead structural class of compound has been identified with the potential for modification into potent, cell-penetrant, and efficacious inhibitors of ATP-citrate lyase.

  DOI：

  10.1021/jm960167w

文献信息

• Discovery, design and synthesis of novel potent and selective sphingosine-1-phosphate 4 receptor (S1P4-R) agonists
  作者：Miguel Guerrero、Mariangela Urbano、Jian Zhao、Melissa Crisp、Peter Chase、Peter Hodder、Marie-Therese Schaeffer、Steven Brown、Hugh Rosen、Edward Roberts

  DOI：10.1016/j.bmcl.2011.10.096

  日期：2012.1

  potent and selective S1P4-R hit agonist. Design, synthesis and systematic structure–activity relationships study of the HTS-derived hit led to the development of novel potent S1P4-R agonists exquisitely selective over the remaining S1P1–3,5-Rs family members. Remarkably, the molecules herein reported provide novel pharmacological tools to decipher the biological function and assess the therapeutic utility

  S1P 4受体 (S1P 4 -R) 的高亲和力和选择性小分子激动剂可能在包括自身免疫性疾病、病毒感染和血小板减少症在内的多种疾病领域具有重要的治疗效用。分子库-小分子库库的高通量筛选 (HTS) 鉴定出 3-(2-(2,4-dichlorophenoxy)ethoxy)-6-methyl-2-nitropyridine 是一种中等效力和选择性的 S1P 4 -R击中激动剂。HTS 衍生命中的设计、合成和系统的结构-活性关系研究导致了新型强效 S1P 4 -R 激动剂的开发，该激动剂对剩余的 S1P 1-3,5 具有极好的选择性-Rs 家庭成员。值得注意的是，本文报道的分子提供了新的药理学工具来破译生物学功能并评估 S1P 4 -R的治疗效用。
• Spermicidal 1-bis(arylalkyl)alkylimidazoles
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0064244A1

  公开（公告）日：1982-11-10

  New compounds of the formula wherein: Ar1 and Ar2 are each independently optionally substituted phenyl; R', R2 and R3 are each independently hydrogen or alkyl; a is an integer from 1-3; b is an integer from 1-3; c is an integer from 0-2; and d is an integer from 0-2, such that (c + d) equals 0-2; and the pharmaceutically acceptable non-toxic acid addition salts thereof, are spermicidal and, therefore, are useful as contraceptives.

  式中的新化合物 其中 Ar1 和 Ar2 各自独立地为任选取代的苯基； R'、R2 和 R3 各自独立地为氢或烷基 a 是 1-3 的整数 b 是 1-3 的整数 c 是 0-2 的整数；以及 d 是 0-2 的整数，这样 (c + d) 等于 0-2；其药学上可接受的无毒酸加成盐具有杀精子作用，因此可用作避孕药。